All of us, every single man, woman, and child on the face of the Earth were born with the same unalienable rights; to life, liberty and the pursuit of happiness. And, if the governments of the world can't get that through their thick skulls, then, regime change will be necessary.
Wednesday, April 15, 2020
SHOCK REPORT: Top Israeli Mathematician Claims COVID-19 Peaks After 40 Days With or Without Economic Lockdowns — FIRE FAUCI AND BIRX!
The first two patients who were treated with a new Israeli treatment for the novel COVID-19
after testing positive have shown significant improvement, with one of them even being removed from the intensive care unit (ICU) within days of treatment.
Israeli biopharmaceutical RedHill Biopharma Ltd. administered their experimental drug, Opaganib, in Israel for the first time last week. The first two patients treated, according to the company, have demonstrated significant improvement through clinical trial within mere days of treatment.
"We are very encouraged by the preliminary findings showing clinical improvement in the first COVID-19 patients treated with Opaganib, which further supports its safety and potential benefit to patients," said Medical Director at RedHill, Mark L. Levitt, MD, Ph.D. "Our hope is that the unique mechanism of action of Opaganib, with both anti-viral and anti-inflammatory activity, will help COVID-19 patients by reducing lung inflammation, and thus preventing the disease from progressing to a stage which requires mechanical ventilation.
Importantly, Opaganib is targeting a critical host factor that the coronavirus is unlikely to evade via mutation in possible future outbreaks of the pandemic."
1 comment:
A cure shows results on its first human experiments.
https://www.jpost.com/HEALTH-SCIENCE/New-Israeli-COVID-19-treatment-seemingly-successful-with-first-two-patients-624722
The first two patients who were treated with a new Israeli treatment for the novel COVID-19
after testing positive have shown significant improvement, with one of them even being removed from the intensive care unit (ICU) within days of treatment.
Israeli biopharmaceutical RedHill Biopharma Ltd. administered their experimental drug, Opaganib, in Israel for the first time last week. The first two patients treated, according to the company, have demonstrated significant improvement through clinical trial within mere days of treatment.
"We are very encouraged by the preliminary findings showing clinical improvement in the first COVID-19 patients treated with Opaganib, which further supports its safety and potential benefit to patients," said Medical Director at RedHill, Mark L. Levitt, MD, Ph.D. "Our hope is that the unique mechanism of action of Opaganib, with both anti-viral and anti-inflammatory activity, will help COVID-19 patients by reducing lung inflammation, and thus preventing the disease from progressing to a stage which requires mechanical ventilation.
Importantly, Opaganib is targeting a critical host factor that the coronavirus is unlikely to evade via mutation in possible future outbreaks of the pandemic."
Post a Comment